Evidence map›Paper›PMID 35616801›Full record

ArticleMetabolic brain disease2022

Thiazolidine-2,4-dione derivative exhibits antitumoral effect and reverts behavioral and metabolic changes in a model of glioblastoma.

Alana de Vasconcelos, Larissa Ribeiro de Moura, Nathalia Stark Pedra, Natália Pontes Bona, Mayara Sandrielly Pereira Soares, Magno da Silva Marques, Ana Paula Horn, Luiza Spohr, Roselia Maria Spanevello, Francieli Moro Stefanello and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Alana de VasconcelosLaboratório de Química Aplicada à Bioativos (LaQuiABio), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Larissa Ribeiro de MouraLaboratório de Química Aplicada à Bioativos (LaQuiABio), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Nathalia Stark PedraLaboratório de Neuroquímica, Inflamação e Câncer (Neurocan), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Natália Pontes BonaLaboratório de Neuroquímica, Inflamação e Câncer (Neurocan), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Mayara Sandrielly Pereira SoaresLaboratório de Neuroquímica, Inflamação e Câncer (Neurocan), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Magno da Silva MarquesInstituto de Ciências Biológicas - Morfologia, Universidade Federal de Rio Grande, Rio Grande, RS, Brazil.
Ana Paula HornInstituto de Ciências Biológicas - Morfologia, Universidade Federal de Rio Grande, Rio Grande, RS, Brazil.
Luiza SpohrLaboratório de Neuroquímica, Inflamação e Câncer (Neurocan), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Roselia Maria SpanevelloLaboratório de Neuroquímica, Inflamação e Câncer (Neurocan), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Francieli Moro StefanelloLaboratório de Neuroquímica, Inflamação e Câncer (Neurocan), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil. francieli.stefanello@ufpel.edu.br.
Wilson CunicoLaboratório de Química Aplicada à Bioativos (LaQuiABio), Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Universidade Federal de Pelotas · BRUniversidade Federal do Rio Grande · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to evaluate the anti-glioma activity of 3-(4-fluorobenzyl)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione (AV23) in a preclinical model of glioblastoma, as well as behavioral parameters and toxicological profile. The implantation of C6 cells in the left striatum of male Wistar rats was performed by stereotaxic surgery. After recovery, animals were treated with vehicle (canola oil) or AV23 (10 mg/kg/day) intragastrically for 15 days. It was found that AV23 reduced tumor volume by 90%. Serum biochemical parameters such as triglycerides, cholesterol, HDL-cholesterol, LDL-cholesterol, albumin, aspartate aminotransferase, urea, creatinine and total proteins were not changed; however, there was a slight increase in alanine aminotransferase. The compound AV23 reverted the hypoglycemia and the reduction in body weight caused by glioblastoma. Additionally, AV23 was able to revert the reduction of locomotion caused by the tumor implantation. Therefore, the compound AV23 can be considered a promising candidate in the treatment of glioblastoma.

Indexed as

GlioblastomaThiazolidinedionesAnimalsMaleRatsRats, WistarThiazolidinesthiazolidine-2,4-dioneThiazolidinedionesThiazolidinesBehavioral parametersGlioblastomaThiazolidine-2,4-dioneToxicity

Identifiers

PMID35616801
OpenAlexW4281561590

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.